ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

swirl technologies pty ltd t/a parker healthcare -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

multigate medical devices pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - 17605 - blood cell wash set, autotransfusion - the autotransfusion kit is a collection of sterile disposable plastic tube segments and associated items (eg connectors, adapters, re infusion bags, reservoir container) designed to collect, defoam, filter and handle the blood being processed in an autotransfusion unit for blood recovery before the blood is re infused into the patient.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

itl australia pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

terumo australia pty ltd -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

mediplast australia pty ltd - 46263 - blood recovery autotransfusion system, manual - used to manually collect, filter, and re-infuse intraoperative and/or postoperative autologous blood shed during and/or after elective and non-elective surgery. it is a complete, closed-circuit system. the device is typically used when a lack of donor blood or when compatible blood is not available.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

novartis europharm limited - deferasirox - beta-thalassemia; iron overload - all other therapeutic products - exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

roche registration gmbh - epoetin beta - kidney failure, chronic; anemia; cancer; blood transfusion, autologous - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anaemia (hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).